Head-to-head independent study shows use of GE Healthcare’s Visipaque leads to better image quality


GE Healthcare announced results from an independent study, which showed that use of isosmolar contrast agent Visipaque 320 (iodixanol 320mg I/ml) provides better image quality of coronary stents during multi-detector CT coronary angiography (MDCT-CA) than use of Iomeron 400 (iomeprol 400mg l/ml) when injected at the same flow rate (5.0 ml/s) and volume (80ml). Patients injected with Visipaque at 5.0 ml/s also experienced less heat sensation, fewer premature heart beats and their overall heart rate (HR) was less affected during scanning. The data were published online in Journal of Cardiovascular Computed Tomography.

“Although multi-detector CT coronary angiography is increasingly used as a non-invasive tool for evaluating coronary stents and bypass grafts, it was unknown until now, whether iodinated contrast medium characteristics affected diagnostic performance” says Daniele Andreini, lead author of the study, Centro Cardiologico Monzino, Milan, Italy.

This study evaluated 254 patients undergoing MDCT-CA coronary stent follow-up with Iomeron 400 at 5.0 ml/s flow rate (group 1, n=83), Visipaque 320 at 6.2 ml/s flow rate (group 2, n=87) and Visipaque 320 at 5.0 ml/s flow rate (group 3, n=84). Heart rate immediately before and at the end of scanning, heart rate variation, premature heart beats and heat sensation by visual analogue scale after scanning were recorded.

The study found overall stent evaluability was significantly higher in patients who received Visipaque 320 at 5.0 ml/s than those who received Visipaque 320 6.2 ml/s (98% vs. 91%) or Iomeron 400 5.0 ml/s (98% vs. 92%) due to a lower number of severe artefacts in group 3 (n=7) as compared to groups 2 (n=21) and 1 (n=26).